Roche in Russia

Last updated: 01.06.2015

Address: 107031, Москва, Трубная площадь, дом 2, Бизнес-центр ‘Неглинная Плаза’,Russia

Tel: +7 (495) 229-29-99


Company description

Roche’ subsidiary in Russia was opened in 1991 and since then the company’s biotechnological medicines for the treatment of cancer, severe virus infections, autoimmune inflammatory diseases and metabolic disorders are widely marketed in Russia. The headquarters are located in Moscow, with subsidiaries in Saint-Petersburg and Novosibirsk. Roche’s development of novel and highly effective medicines is the result of numerous clinical trials conducted by the company according to GCP (Good Clinical Practice) worldwide, including Russia. Clinical trials in Russia are performed in the context of long-term cooperation with major Russian research centers. The leaders among them are Russian N.N. Blokhin Oncology Scientific Center in Moscow, Prof. N.N. Petrov Cancer Research Institute in Saint-Petersburg, Republican Oncology Center and AIDS Center in Kazan and many others. Roche closely monitors the quality of both local trials and parts of multinational clinical projects conducted in Russia.

A large number of Roche’s medicines are included into the Federal Reimbursement List due to the Federal program of reimbursement of certain categories of citizens. The company is a Good Corporate Citizen and takes an active part in social healthcare projects and initiatives. Roche supports the Equal Right to Life program initiated by oncologists. The goal of the program is to implement modern technologies of cancer diagnostics and treatment into regional healthcare institutions and to provide equal opportunities to proper treatment to all patients regardless of their social status or location.

Additional information on Roche in Russia can be found at

The Roche company was founded in 1896 in Basel, Switzerland. At present Roche has subsidiaries in 150 countries worldwide and employs over 80,000 people. The investment in research and development in 2010 was over 9 billion Swiss francs , with Group sales of 47,5 billion Swiss francs. Roche wholly owns Genentech, USA and has a majority stake in Chugai Pharmaceutical, Japan.

Products and services

Roche is one of the leading global pharmaceutical companies and the world’s leader in in vitro diagnostics and tissue-based cancer diagnostics. Personalised medicine strategy allows Roche to develop novel medicines and diagnostics tools that save and prolong patients’ lives significantly improving their quality of life.


We use cookies to ensure that we give you the best experience on our site. For more info click here